MT. KISCO, N.Y., May 29, 2013 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that the company has appointed Joseph V. DiTrolio, M.D. as the Chief Medical Officer, United States.
Dr. DiTrolio is a Diplomate of the American Board of Urology, a Clinical Professor of Surgery, Division of Urology at New Jersey Medical School, the Treasurer, Board of Governors for the Stone Center of New Jersey, and the immediate past Chairman of the Department of Urology for the St. Barnabas Medical Center Healthcare System. Dr. DiTrolio has served as a medical consultant for Fortune 500 Healthcare companies including Novartis, Sanofi-Aventis, AstraZeneca, and Allergan.
Dr. DiTrolio commented, "After extensive research, I am very excited about ImmuDyne's future. I believe my Corporate relationships, along with my medical experience, will be quite beneficial to the Company and our shareholders, both in the short- and long-term."
President and CEO Mark McLaughlin stated, "We are honored that Dr. DiTrolio chose to bring his world-class talents to ImmuDyne. In our opinion, this is a watershed moment. We expect Joe to play an integral role in ImmuDyne's growing future."
Karen Kingston, Chief Marketing Officer went on to say, "Dr. DiTrolio has joined our team at a critical time as the company enters into new areas of expansion and growth. In the immediate future, we will look to Dr. DiTrolio's expertise and guidance as ImmuDyne prepares to rollout new dietary supplement product lines through physician networks and practices."
ImmuDyne is a health and wellness lifestyle company. ImmuDyne has a portfolio of unique patent-protected products with applications in the wellness lifestyle, skin care, anti-aging, fitness, and health markets. ImmuDyne has offices located in Mt. Kisco, NY, Carlsbad, CA, and Florence, KY.
ImmuDyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com. Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
ImmuDyne, Inc. Mark McLaughlin 914-714-8901 MarkMcL@immudyne.com